Verkkogrifols, a global leader in plasma medicines, has received fda approval for its new immunoglobulin (ig) purification and filling facility at its clayton.
Verkkodata from a new investigational drug that could alter the standard treatment for a rare blood disease suggests it has the potential to delay or prevent.